Leukogene Therapeutics, Inc., based in Charleston, SC, is an oncology-focused biotech company and a spin-out from the Medical University of South Carolina (MUSC). Our mission is to deliver innovative immunotherapies for hard-to-treat cancers, with a particular emphasis on immunologically "cold" tumors. 
 
Our proprietary Major Histocompatibility Complex (MHC) class II targeted M2T™ immunotherapy platform directs and mobilizes the immune system to trigger a robust, tumor antigen-specific immune response and eliminate tumor cells. 
 
Preclinical work is ongoing to support Leukogene’s first planned IND filing in mid-2026 for our lead clinical candidate, M2T-CD33, in Acute Myelogenous Leukemia (AML). Our discovery pipeline includes additional compounds intended to address unmet needs in solid tumors, including pancreatic cancer, and other hematology/oncology indications.

Leukogene has a highly experienced leadership team, including founder Dr. Nathan Dolloff, and CEO, Dr. Sandeep Gupta, a seasoned pharma executive with over 25 years of experience. At Leukogene, we are committed to advancing the field of cancer immunotherapy and bringing transformative therapies to patients in need.

Leukogene Therapeutics, Inc.

Org chart

Teams

Offices

Leukogene Therapeutics, Inc.

Org chart

Teams

Offices

Related companies